Cyfuse Biomedical K.K.
株式会社サイフューズ
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4892
FY2025 (Dec 2025) · J-GAAP · parent-only (non-consolidated) Source: filing S100XV4M
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Dec 2025) runs Jan 1, 2025 – Dec 31, 2025.
| Gross margin | 49.3% |
|---|---|
| Operating margin | -358.5% |
| Net margin | -330.7% |
| Return on equity | -29.7%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | -19.6% |
| Revenue growth (YoY) | 324.3% |
| EPS (basic) | −¥86.78 |
| EPS growth (YoY) | —Base is zero or negative |
| Current ratio | 4.54x |
| Equity ratio | 62.3% |
| Book value / share | ¥276.42 |
| Free cash flow | −¥582M |